Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (11): 1015-1020.DOI: 10.3969/j.issn.1673-8640.2019.11.013
• Orginal Article • Previous Articles Next Articles
ZHOU Mi1, SHEN Ruojian1, WU Weiyun1, YAN Hongmei2, GUO Wei1, PAN Baishen1, WANG Beili1()
Received:
2018-09-10
Online:
2019-11-30
Published:
2019-12-05
CLC Number:
ZHOU Mi, SHEN Ruojian, WU Weiyun, YAN Hongmei, GUO Wei, PAN Baishen, WANG Beili. Performance evaluation and clinical application of 1,5-anhydrous sorbitol determination by enzymatic method[J]. Laboratory Medicine, 2019, 34(11): 1015-1020.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.11.013
样本 | 批内精密度 | 批间精密度 | |||||
---|---|---|---|---|---|---|---|
x(μmol/L) | s(μmol/L) | CV(%) | x(μmol/L) | s(μmol/L) | CV(%) | ||
低值 | 21.4 | 0.73 | 3.43 | 22.3 | 0.70 | 3.14 | |
中值 | 77.2 | 0.81 | 1.05 | 78.1 | 0.83 | 1.06 | |
高值 | 129.3 | 0.78 | 0.60 | 132.6 | 1.36 | 1.02 |
样本 | 批内精密度 | 批间精密度 | |||||
---|---|---|---|---|---|---|---|
x(μmol/L) | s(μmol/L) | CV(%) | x(μmol/L) | s(μmol/L) | CV(%) | ||
低值 | 21.4 | 0.73 | 3.43 | 22.3 | 0.70 | 3.14 | |
中值 | 77.2 | 0.81 | 1.05 | 78.1 | 0.83 | 1.06 | |
高值 | 129.3 | 0.78 | 0.60 | 132.6 | 1.36 | 1.02 |
组别 | 例数 | 年龄(岁) | 性别 | ALT(U/L) | AST(U/L) | ALP(U/L) | ||||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||
DM组 | 148 | 64.04±7.8* | 88 | 60 | 18.5(12.1~24.3)* | 18.0(11.0~25.0)** | 69.0(54.1~83.9) | |||
非DM组 | 56 | 62.23±6.7 | 50 | 6 | 37.0(23.8~50.3) | 56.5(37.6~74.9) | 76.5(63.6~89.4) | |||
组别 | GGT(U/L) | BUN(mmol/L) | Cr (μmol/L) | UA(μmol/L) | ||||||
DM组 | 27.5(18.5~36.5) | 5.6(4.3~6.9) | 70.0(54.6~85.4) | 320.5(245.9~395.1) | ||||||
非DM组 | 36.5(25.1~47.9) | 5.2(3.9~6.5) | 80.0(68.3~91.8) | 361.0(289.4~432.6) | ||||||
组别 | Glu(mmol/L) | GA(%) | HbA1c(%) | β-HB(mmol/L) | ||||||
DM组 | 8.3(5.5~11.1)* | 22(16~28)** | 8.3(7.0~9.6)** | 0.10(0.08~0.12)* | ||||||
非DM组 | 5.9(4.9~6.9) | 14(12~16) | 5.6(5.4~5.8) | 0.09(0.06~0.12) | ||||||
组别 | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | 1,5-AG(μmol/L) | |||||
DM组 | 4.3(3.5~5.1) | 1.5(0.9~2.2) | 0.3(0.2~0.4)* | 2.3(1.7~2.9) | 20.0(14.0~26.0)** | |||||
非DM组 | 4.2(3.4~5.0) | 1.2(0.7~1.7) | 1.1(0.9~1.3) | 2.3(1.5~3.1) | 135.0(68.0~202.0) |
组别 | 例数 | 年龄(岁) | 性别 | ALT(U/L) | AST(U/L) | ALP(U/L) | ||||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||
DM组 | 148 | 64.04±7.8* | 88 | 60 | 18.5(12.1~24.3)* | 18.0(11.0~25.0)** | 69.0(54.1~83.9) | |||
非DM组 | 56 | 62.23±6.7 | 50 | 6 | 37.0(23.8~50.3) | 56.5(37.6~74.9) | 76.5(63.6~89.4) | |||
组别 | GGT(U/L) | BUN(mmol/L) | Cr (μmol/L) | UA(μmol/L) | ||||||
DM组 | 27.5(18.5~36.5) | 5.6(4.3~6.9) | 70.0(54.6~85.4) | 320.5(245.9~395.1) | ||||||
非DM组 | 36.5(25.1~47.9) | 5.2(3.9~6.5) | 80.0(68.3~91.8) | 361.0(289.4~432.6) | ||||||
组别 | Glu(mmol/L) | GA(%) | HbA1c(%) | β-HB(mmol/L) | ||||||
DM组 | 8.3(5.5~11.1)* | 22(16~28)** | 8.3(7.0~9.6)** | 0.10(0.08~0.12)* | ||||||
非DM组 | 5.9(4.9~6.9) | 14(12~16) | 5.6(5.4~5.8) | 0.09(0.06~0.12) | ||||||
组别 | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | 1,5-AG(μmol/L) | |||||
DM组 | 4.3(3.5~5.1) | 1.5(0.9~2.2) | 0.3(0.2~0.4)* | 2.3(1.7~2.9) | 20.0(14.0~26.0)** | |||||
非DM组 | 4.2(3.4~5.0) | 1.2(0.7~1.7) | 1.1(0.9~1.3) | 2.3(1.5~3.1) | 135.0(68.0~202.0) |
组别 | 例数 | 年龄(岁) | 性别 | ALT(U/L) | AST(U/L) | ALP(U/L) | ||||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||
DM合并AMI组 | 78 | 62.50±7.4 | 52 | 26 | 36.0(20.0~52.0)** | 63.0(50.0~76.0)** | 74.5(62.4~86.6) | |||
单纯DM组 | 70 | 63.50±7.2 | 36 | 34 | 18.0(11.0~25.0) | 17.0(12.0~22.0) | 69.5(53.9~85.1) | |||
组别 | GGT(U/L) | BUN(mmol/L) | Cr (μmol/L) | UA(μmol/L) | ||||||
DM合并AMI组 | 37.0(22.0~52.0) | 5.5(4.0~7.0) | 80.0(57.0~103.0) | 361.1(307.3~415.2) | ||||||
单纯DM组 | 26.0(15.0~37.0) | 5.4(4.2~5.6) | 67.0(37.0~97.0) | 306.3(240.2~372.1) | ||||||
组别 | Glu(mmol/L) | GA(%) | HbA1c(%) | β-HB(mmol/L) | ||||||
DM合并AMI组 | 6.4(4.8~8.0) | 15(12~18)** | 5.7(4.7~6.7)** | 0.10(0.06~0.14) | ||||||
单纯DM组 | 7.9(5.0~10.8) | 22(16~28) | 8.3(7.0~9.6) | 0.09(0.07~0.11) | ||||||
组别 | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | 1,5-AG(μmol/L) | |||||
DM合并AMI组 | 4.3(3.5~5.1) | 1.4(0.8~2.0) | 1.1(0.9~1.3) | 2.4(1.2~3.6) | 114.0(54.3~173.8)** | |||||
单纯DM组 | 4.2(3.5~4.9) | 1.5(0.9~2.1) | 1.0(0.8~1.2) | 2.3(1.7~2.9) | 18.5(4.0~33.0) |
组别 | 例数 | 年龄(岁) | 性别 | ALT(U/L) | AST(U/L) | ALP(U/L) | ||||
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||
DM合并AMI组 | 78 | 62.50±7.4 | 52 | 26 | 36.0(20.0~52.0)** | 63.0(50.0~76.0)** | 74.5(62.4~86.6) | |||
单纯DM组 | 70 | 63.50±7.2 | 36 | 34 | 18.0(11.0~25.0) | 17.0(12.0~22.0) | 69.5(53.9~85.1) | |||
组别 | GGT(U/L) | BUN(mmol/L) | Cr (μmol/L) | UA(μmol/L) | ||||||
DM合并AMI组 | 37.0(22.0~52.0) | 5.5(4.0~7.0) | 80.0(57.0~103.0) | 361.1(307.3~415.2) | ||||||
单纯DM组 | 26.0(15.0~37.0) | 5.4(4.2~5.6) | 67.0(37.0~97.0) | 306.3(240.2~372.1) | ||||||
组别 | Glu(mmol/L) | GA(%) | HbA1c(%) | β-HB(mmol/L) | ||||||
DM合并AMI组 | 6.4(4.8~8.0) | 15(12~18)** | 5.7(4.7~6.7)** | 0.10(0.06~0.14) | ||||||
单纯DM组 | 7.9(5.0~10.8) | 22(16~28) | 8.3(7.0~9.6) | 0.09(0.07~0.11) | ||||||
组别 | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | 1,5-AG(μmol/L) | |||||
DM合并AMI组 | 4.3(3.5~5.1) | 1.4(0.8~2.0) | 1.1(0.9~1.3) | 2.4(1.2~3.6) | 114.0(54.3~173.8)** | |||||
单纯DM组 | 4.2(3.5~4.9) | 1.5(0.9~2.1) | 1.0(0.8~1.2) | 2.3(1.7~2.9) | 18.5(4.0~33.0) |
[1] | YAMANOUCHI T,AKANUMA Y.Serum 1,5-anhydroglucitol(1,5 AG):new clinical marker for glycemic control[J]. Diabetes Res Clin Pract,1994,24(Suppl):S261-S268. |
[2] | KOGA M,KASAYAMA S.Clinical impact of glycated albumin as another glycemic control marker[J]. Endocr J,2010,57(9):751-762. |
[3] | American Diabetes Association.Standards of medical care in diabetes-2012[J]. Diabetes Care,2012,35(Suppl 1):S11-S63. |
[4] | SELVIN E,CRAINICEANU C M,BRANCATI F L,et al.Short-term variability in measures of glycemia and implications for the classification of diabetes[J]. Arch Intern Med,2007,167(14):1545-1551. |
[5] | PITKÄNEN E. 1,5-anhydro-D-glucitol-a novel type of sugar in the human organism[J]. Scand J Clin Lab Invest Suppl,1990,201:55-62. |
[6] | YAMANOUCHI T,TACHIBANA Y,AKANUMA H,et al.Origin and disposal of 1,5-anhydroglucitol,a major polyol in the human body[J]. Am J Physiol,1992,263(2 Pt 1):E268-E273. |
[7] | YAMANOUCHI T,AKANUMA H,NAKAMURA T,et al.Reduction of plasma 1,5-anhydroglucitol(1-deoxyglucose) concentration in diabetic patients[J]. Diabetologia,1988,3(1):41-45. |
[8] | KAMETANI S,HASHIMOTO Y,YAMANOUCHI T,et al.Reduced renal reabsorption of 1,5-anhydro-D -glucitol in diabetic rats and mice[J]. J Biochem,1987,102(6):1599-1607. |
[9] | BUSE J B,FREEMAN J L,EDELMAN S V,et al. Serum 1,5-anhydroslucitol(GlycoMark):a short-term glycemic marker[J]. Diabetes Technol Ther,2003,5(3):355-363. |
[10] | 张颖,于永光,刘倩. 酶偶联法测定1,5-脱水葡糖苷方法学建立[J]. 中华临床医师杂志(电子版),2012,6(4):1031-1032. |
[11] | FUKUMURA Y,TAJIMA S,OSHITANI S,et al.Fully enzymatic method for determining 1,5-anhydro-D-glucitol in serum[J]. Clin Chem,1994,40(11 Pt 1):2013-2016. |
[12] | 郭建华,李莉,李晓强,等. 两种全酶法测定1,5-脱水葡萄糖醇方法比较[J]. 郧阳医学院学报,2005,24(4):238-239. |
[13] | SAGLAM B,UYSAL S,SOZDINLER S,et al.Diagnostic value of glycemic markers HbA1c,1,5-anhydroglucitol and glycated albumin in evaluating gestational diabetes mellitus[J]. Ther Adv Endocrinol Metab,2017,8(12):161-167. |
[14] | WANG Y,YUAN Y,ZHANG Y,et al.Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes[J]. Acta Diabetol,2017,54(5):425-431. |
[15] | JAGANNATHAN R,SEVICK M A,FINK D,et al.The 1-hour post-load glucose level is more effective than HbA1c for screening dysglycemia[J]. Acta Diabetol,2016,53(4):543-550. |
[16] | KO G T,CHAN J C,YEUNG V T,et al.Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects[J]. Diabetes Care,1998,21(8):1221-1225. |
[17] | 张抗,万雄萍. 血浆1,5脱水葡糖醇在糖尿病监测中的应用和测定方法的进展[J]. 临床检验杂志,2000,18(6):378-380. |
[18] | 张颖,朱铁虹. 1,5-脱水山梨醇对糖尿病早期诊断的意义[J]. 医学综述,2008,14(7):1077-1079. |
[19] | KIM K K,JUNG H S,KWAK S H,et al.1,5-Anhydro-D-glucitol could reflect hypoglycemia risk in patients with type 2 diabetes receiving insulin therapy[J]. Endocrinol Metab(Seoul),2016,31(2):284-291. |
[20] | SELVIN E,RAWLINGS A,LUTSEY P,et al.Association of 1,5-anhydroglucitol with cardiovascular disease and mortality[J]. Diabetes,2016,65(1):201-208. |
[1] | LIANG Chaohui, ZHAO Fan, LIU Qianwen. Relationship between macrophage migration inhibitory factor and carotid vascular calcification in elderly patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2023, 38(5): 460-465. |
[2] | DENG Xu, ZHUANG Wenlong, XUE Hui, ZHU Shuqin, LI Ying. Relationship between neutrophil/lymphocyte ratio,fibrinogen and carotid intima-media thickness in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(4): 368-372. |
[3] | CHEN Hui, CHEN Guanghui, LIANG Yingliang, WANG Wandang, YIN Zhijun. Screening hub genes and diagnostic analysis of gestational diabetes mellitus based on GEO database [J]. Laboratory Medicine, 2023, 38(3): 276-281. |
[4] | KE Qiulei, HUANG Jing, CHEN Aizheng, SONG Yanfeng, SU Xiaofeng. Subgingival flora and the relations between periodontal health indexes and risk of periodontal disease in patients with GDM [J]. Laboratory Medicine, 2023, 38(2): 163-166. |
[5] | WU Ying, ZHANG Lihong, GAO Yin. Predictive value of high-density lipoprotein cholesterol on the risk of cerebral ischemic stroke in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(11): 1052-1056. |
[6] | QIAN Linyu, LIANG Weifang, TANG Sichen. Determination and clinical significance of NLRP3,CTRP6 and IL-1β in patients with gestational diabetes mellitus [J]. Laboratory Medicine, 2023, 38(10): 936-940. |
[7] | XING Baobao, CAO Yinfang. Predictive value of sd-LDL-C/LDL-C ratio for in-stent restenosis in patients with AMI after interventional therapy [J]. Laboratory Medicine, 2023, 38(10): 941-945. |
[8] | WANG Lingling, REN Chunli. Correlation of MTHFR gene C677T polymorphism and blood lipid levels with GDM [J]. Laboratory Medicine, 2022, 37(6): 543-546. |
[9] | ZHANG Xiaoqin, ZHOU Yulan, FU Zhumei, HAN Xuexue, ZHAN Jie. Relationship of mtDNA T16189C mutation and gestational diabetes mellitus [J]. Laboratory Medicine, 2022, 37(5): 413-416. |
[10] | ZHENG Jiahua, YAO Yanying, GAO Qingling, DONG Ye. Predictive values of Lp(a) and apoB/apoA-1 ratio for the occurrence of MACE in patients with AMI after interventional therapy [J]. Laboratory Medicine, 2022, 37(12): 1141-1145. |
[11] | MA Jianguo, ZHU Xiaolin, DING Yongguang, YIN Meng, LI Hongchun. Predictive values of red blood cell distribution width and myocardial markers for acute myocardial infarction in patients with CAS [J]. Laboratory Medicine, 2022, 37(12): 1164-1168. |
[12] | QU Yuanqing, ZHAO Fan, YE Ailian, LI Lifeng, ZHAO Haitao, LI Huizhen, LIANG Zhuohui, LI Liang. Relationship between plasma omentin-1 level and metabolic clearance rate in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2022, 37(1): 28-31. |
[13] | YUE Daoyuan, CHEN Wei, LIAO Qing, YU Weiting, LI Huijun. Establishment and evaluation of Wuhan Glycohemoglobin Harmonization Program [J]. Laboratory Medicine, 2022, 37(1): 78-82. |
[14] | LE Jiangman, LI Tianyuan, TAN Meiyu, WANG Yajie, ZHOU Lida, SHU Jie, WU Jiaoxiang, SUN Hanxiao, XUAN Binbin, CAI Xushan, SHENG Huiming. Correlation of gestational diabetes mellitus with plasma TMAO [J]. Laboratory Medicine, 2021, 36(8): 795-799. |
[15] | WANG Yu, ZHANG Wenwen, LIU Meiling, LIU Xiaojuan. Relationship between AFP,free-βHCG,uE3 and GDM in the second trimester of pregnancy [J]. Laboratory Medicine, 2021, 36(8): 828-832. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||